myxovirus
influenza
viru
iav
respiratori
syncyti
viru
rsv
major
human
pathogen
mandat
develop
novel
therapeut
establish
highthroughput
screen
protocol
simultan
identif
pathogenand
hosttarget
hit
candid
either
pathogen
attempt
coinfect
cell
iav
rsv
howev
viral
replic
kinet
incompat
rsv
signal
window
low
iavdriven
minireplicon
report
assay
use
initi
screen
narrow
host
cell
rang
restrict
singlecycl
infect
overcom
limit
develop
rsv
strain
carri
firefli
luciferas
fuse
innov
univers
smallmolecul
assist
shutoff
domain
boost
assay
signal
window
hyperact
fusion
protein
synchron
iav
rsv
report
express
kinet
suppress
identif
rsv
entri
inhibitor
sensit
recent
report
rsv
panresist
mechan
combin
replicationcompet
recombin
iav
strain
harbor
nanoluciferas
assay
perform
well
human
respiratori
cell
line
support
multicycl
infect
miniatur
format
protocol
valid
screen
set
nih
clinic
collect
ncc
quadrupl
test
screen
demonstr
favor
assay
paramet
reproduc
applic
lopac
librari
bioactiv
compound
proofofconcept
campaign
detect
licens
antimyxoviru
therapeut
ribavirin
neuraminidas
inhibitor
zanamivir
identifi
two
unexpect
rsvspecif
hit
candid
fenretinid
opioid
receptor
antagonist
hit
evalu
direct
orthogon
doserespons
counterscreen
use
standard
recrsv
report
strain
express
renilla
luciferas
myxoviru
famili
includ
major
human
respiratori
pathogen
influenza
viru
rsv
measl
viru
mev
highli
pathogen
henipavirus
rsv
influenza
virus
pharmaceut
relev
rsv
member
paramyxoviru
famili
lead
caus
infant
hospit
due
viral
infect
unit
state
respons
major
viral
death
among
children
one
year
age
approxim
winter
infant
cohort
patient
hospit
us
rsv
diseas
annual
infant
born
prematur
bronchopulmonari
dysplasia
congenit
heart
defect
highest
risk
develop
sever
rsv
diseas
reinfect
rsv
occur
throughout
life
rsv
lifethreaten
elderli
immunocompromis
clinic
symptom
human
infect
major
paramyxoviru
pathogen
mev
domin
host
immunopatholog
close
window
therapeut
intervent
onset
symptom
case
rsv
howev
sever
studi
challeng
paradigm
rsv
pathogenesi
result
host
immunopatholog
alon
higher
viral
load
identifi
predict
sever
lower
respiratori
rsv
infect
infant
rsv
load
day
three
hospit
associ
requir
intens
care
respiratori
failur
children
less
two
year
old
observ
suggest
efficaci
therapeut
given
earli
hospit
children
may
improv
downstream
morbid
reduc
immunopatholog
open
opportun
improv
diseas
manag
rsv
elicit
innat
adapt
immun
respons
viru
poorli
immunogen
overal
neutral
antibodi
titer
wane
quickli
post
infect
make
vaccin
develop
challeng
despit
extens
research
immunoprophylaxi
neutral
antibodi
palivizumab
reserv
highrisk
patient
due
prohibit
cost
ribavirin
although
approv
rsv
treatment
littl
clinic
benefit
due
efficaci
toxic
issu
iav
account
million
infect
per
year
repres
overal
lead
caus
human
respiratori
diseas
due
viral
infect
us
alon
season
influenza
alon
respons
death
per
year
pose
substanti
econom
burden
due
decreas
product
healthcar
cost
associ
hospit
andor
treatment
morbid
mortal
associ
pandem
emerg
highli
pathogen
influenza
strain
substanti
higher
current
season
influenza
vaccin
show
efficaci
vaccin
adult
elderli
neuraminidas
inhibitor
predomin
class
antiinfluenza
viru
therapeut
oseltamivir
still
primari
drug
stockpil
pandem
prepared
recommend
treatment
season
iav
influenza
b
viru
strain
howev
efficaci
human
moder
subject
debat
issu
aggrav
emerg
resist
oseltamivir
affect
season
pandem
highli
pathogen
avian
influenza
strain
develop
novel
therapeut
iav
rsv
infect
urgent
need
address
signific
morbid
mortal
high
socioeconom
toll
emerg
strain
preexist
resist
avail
antivir
experi
pathogen
hosttarget
antivir
experienc
renaiss
last
decad
base
promis
combin
low
frequenc
emerg
viral
resist
broaden
antivir
indic
spectrum
howev
hostdirect
approach
inher
higher
risk
induc
unaccept
side
effect
efficaci
compromis
altern
host
pathway
function
replac
therapeut
target
pathway
vivo
tangibl
advantag
associ
hostdirect
antivir
narrowli
design
drug
discoveri
campaign
inher
challeng
risk
earli
stage
failur
due
shallow
candid
pool
search
resourceeffect
approach
simultan
interrog
full
hostpathogen
interactom
pathogendirect
hostdirect
hit
candid
singl
well
set
recent
describ
dual
myxoviru
pathogen
high
throughput
screen
ht
assay
base
hypothesi
anticip
broaden
indic
spectrum
hostdirect
antivir
employ
selector
hit
candid
combin
first
implement
strategi
iav
isol
drive
firefli
luciferas
minigenom
report
recombin
mev
report
strain
express
renilla
luciferas
mev
paramyxoviru
chosen
replac
rsv
sinc
found
fast
iav
slow
rsv
report
express
kinet
incompat
demonstr
orthoand
paramyxovirus
effici
corepl
thu
allow
autom
identif
orthomyxovirusspecif
paramyxovirusspecif
broadspectrum
drug
candid
robust
assay
format
implement
dualpathogen
protocol
proofofconcept
screen
identifi
amongst
other
panmyxoviru
blocker
compound
act
stimul
express
effector
gene
host
antivir
pathway
despit
confirm
gener
feasibl
pilot
screen
also
highlight
sever
limit
origin
assay
iav
minireplicon
report
resourceintens
sinc
mandat
report
plasmid
transfect
cryopreserv
transfect
cell
prior
seed
highdens
assay
plate
ii
express
minireplicon
construct
must
driven
either
polymeras
rna
polymeras
restrict
conceiv
host
cell
rang
cell
line
stabli
express
polymeras
line
high
intrins
rna
pol
activ
cell
iii
poorli
synchron
iav
rsv
report
express
kinet
necessit
use
recombin
mev
report
strain
paramyxoviru
surrog
exclud
identif
pathogendirect
rsv
inhibitor
therefor
goal
present
studi
develop
implement
feasibl
screen
innov
myxoviru
report
strain
overcom
limit
support
direct
drug
screen
replicationcompet
iav
rsv
report
strain
robust
ht
campaign
human
carcinoma
atcc
human
lung
carcinoma
atcc
human
bronchial
epitheli
atcc
human
embryon
kidney
atcc
madin
darbi
canin
kidney
mdck
atcc
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
babi
hamster
kidney
cell
stabli
express
polymeras
cell
incub
everi
third
passag
presenc
geneticin
lipofectamin
invitrogen
use
transient
transfect
reaction
recombin
iavwsn
strain
gener
use
iav
rescu
system
plasmid
kind
gift
david
steinhauer
emori
univers
recombin
iav
contain
renilla
gaussia
luciferas
report
segment
gener
previous
describ
reciavwsn
harbor
nano
luciferas
segment
construct
analog
reciavwsn
gaussia
briefli
packag
signal
inactiv
silent
mutagenesi
nano
luciferaseencod
open
read
frame
orf
harbor
kdelencod
endoplasm
reticulum
retent
signal
fuse
mutant
orf
recombin
pcr
nano
gaussia
luciferas
gene
amplifi
plasmid
nluccmv
promega
ptkgaussia
thermofish
respect
cleavag
sequenc
porcin
teschoviru
insert
luciferas
orf
copi
origin
packag
signal
insert
downstream
code
cassett
plasmid
sequenc
confirm
reciav
strain
recov
rescu
plasmid
transfect
cell
overlay
transfect
cell
onto
mdck
cell
hour
incub
recov
recombin
amplifi
releas
virion
titer
plaqu
assay
mdck
cell
genet
stabil
test
recombin
virion
passag
consecut
four
time
viru
titer
determin
plaqu
assay
passag
parallel
report
titer
determin
passag
tissu
cultur
infect
dose
tcid
titrat
bioluminesc
readout
use
synergi
biotek
multimod
micropl
reader
equip
substrat
injector
backbon
recombin
rsv
strain
plasmid
contain
fulllength
cdna
copi
chimer
genom
fencod
open
read
frame
replac
rsv
isol
addit
renilla
luciferas
orf
ad
substitut
introduc
f
direct
mutagenesi
helper
vector
harbor
saciisali
fragment
genom
follow
transfer
fulllength
plasmid
sequenc
confirm
creat
recrsv
renilla
recombin
pcr
employ
add
rsv
intergen
junction
flank
region
firefli
luciferas
orf
follow
substitut
renilla
luciferasecontain
bstbiavrii
fragment
recrsv
renilla
equival
fragment
harbor
firefli
luciferas
gener
firesmash
orf
smash
tag
fuse
frame
end
firefli
luciferas
orf
recombin
pcr
follow
addit
rsv
flank
region
bstbiavrii
transfer
full
length
cdna
genom
copi
recrsv
recov
cotransfect
rsv
l
n
p
helper
plasmid
cell
previous
describ
subject
rtpcr
cdna
sequenc
recrsv
stock
grown
cell
inocul
multipl
infect
moi
pfucel
infect
cell
kept
hour
follow
incub
five
seven
day
cellassoci
progeni
viru
releas
one
freezethaw
cycl
titer
determin
tcid
titrat
cell
genet
stabil
test
smash
tag
viru
recov
recrsv
virion
consecut
passag
five
time
cell
progeni
virion
second
fifth
passag
incub
presenc
absenc
asunaprevir
asv
infect
cell
lysat
subject
sdspage
immunoblot
infect
cell
per
well
plate
format
lyse
hour
postinfect
ripa
buffer
sodium
deoxychol
mm
nacl
mm
triscl
ph
mm
edta
mm
sodiumfluorid
proteas
inhibitor
roch
mm
phenylmethylsulfonyl
fluorid
subject
clearanc
centrifug
minut
clear
lysat
dilut
urea
buffer
mm
tri
ph
urea
sodium
dodecyl
sulfat
sd
mm
edta
bromphenolblu
dithiothreitol
denatur
minut
lysat
fraction
gel
electrophoresi
trisglycin
gel
transfer
polyvinyliden
difluorid
pvdf
membran
ge
healthcar
protein
materi
detect
decor
specif
antibodi
direct
firefli
luciferas
thermofish
dehydrogenas
antigapdh
calbiochem
immunoblot
develop
use
mous
igg
light
chainspecif
hrpconjug
secondari
antibodi
jackson
chemidoc
digit
imag
system
biorad
two
altern
strategi
explor
remov
contamin
luciferas
protein
viru
stock
progeni
virion
cultur
supernat
iav
stock
releas
one
freezethaw
cycl
infect
cell
rsv
stock
clear
minut
pellet
minut
pellet
materi
resuspend
tne
buffer
mm
triscl
ph
mm
edta
purifi
onestep
sucros
gradient
tne
buffer
minut
virion
harvest
gradient
intersect
altern
clear
rsv
stock
purifi
polish
size
exclus
bind
chromatographi
passag
dual
function
capto
core
resin
ge
healthcar
use
avant
chromatographi
system
ge
healthcar
purif
either
method
viru
stock
store
aliquot
cell
per
well
plate
format
infect
purifi
viru
stock
differ
moi
specifi
coinfect
specifi
time
point
cell
lyse
situ
glolysi
buffer
promega
five
minut
sampl
transfer
solid
white
plate
lysat
kept
frozen
time
cours
complet
equilibr
ambient
temperatur
simultan
rel
luciferas
activ
determin
use
synergi
reader
injector
add
renillaglo
brightglo
dualglo
substrat
promega
respect
lag
time
read
three
minut
well
valu
express
report
strain
rel
highest
read
record
strain
repres
averag
least
three
independ
repeat
compound
dissolv
dmso
mm
concentr
store
mscreen
softwar
packag
use
electron
compound
manag
ht
data
storag
data
analysi
compound
nih
clinic
collect
ncc
receiv
nih
small
molecul
repositori
plate
inventori
mscreen
reformat
barcod
daughter
plate
use
nimbu
liquid
handler
hamilton
robot
multichannel
pipet
head
addit
known
antimyxoviru
bioactiv
identifi
previou
drug
discoveri
campaign
includ
empti
well
ncc
daughter
plate
thirtytwo
well
plate
receiv
compound
posit
control
anoth
well
receiv
volum
equival
vehicl
dmso
asunaprevir
asv
obtain
santa
cruz
biotechnolog
includ
asv
ad
time
viru
infect
cell
well
seed
white
wallclear
bottom
plate
treat
manual
set
known
bioactiv
dilut
growth
media
dmso
final
concentr
specifi
infect
coinfect
iav
rsv
report
virus
differ
moi
specifi
final
dmso
concentr
vehicleinduc
cytotox
effect
detect
incub
period
luciferas
substrat
inject
directli
assay
plate
rel
bioluminesc
intens
determin
compound
assess
five
replic
quantit
assay
valid
z
valu
calcul
accord
formula
z
c
b
mean
c
mean
b
c
control
b
background
cell
well
inject
barcod
white
wallclear
bottom
plate
use
multiflo
autom
dispens
biotek
equip
dual
peristalt
pump
manifold
collect
second
incub
five
hour
co
compound
ad
final
concentr
nlwell
use
highdens
pin
tool
v
p
scientif
attach
pipet
head
nimbu
liquid
handler
follow
coinfect
recrsv
firesmash
moi
reciav
wsnnanoluc
moi
use
multiflo
dispens
unit
spin
collect
second
incub
hour
co
final
vehicl
dmso
concentr
barcod
sourc
assay
plate
automat
detect
record
nimbu
unit
time
stamp
use
stacker
unit
integr
barcod
reader
biotek
attach
synergi
plate
reader
plate
automat
load
dualglo
substrat
well
inject
bioluminesc
record
three
minut
lag
time
well
substrat
readout
automat
save
plate
barcod
manual
calcul
z
valu
luciferas
activ
posit
vehicl
well
process
detail
twofold
serial
dilut
hit
candid
prepar
plate
three
replic
use
nimbu
liquid
handler
cell
well
plate
serial
dilut
transfer
use
pintool
cell
infect
recrsv
firesmash
moi
recrsv
moi
reciav
wsnnanoluc
moi
left
uninfect
cell
viabil
assess
report
signal
record
outlin
determin
cell
viabil
prestoblu
substrat
life
technolog
ad
incub
cell
topread
fluoresc
excit
nm
emiss
nm
instrument
gain
record
minut
incub
use
synergi
plate
reader
fourparamet
variabl
slope
regress
model
appli
determin
activ
ec
toxic
cc
concentr
mscreen
packag
employ
autom
data
analysi
plate
reader
raw
data
file
togeth
sourc
assay
plate
barcod
map
gener
nimbu
system
directli
import
packag
z
valu
automat
calcul
base
design
control
well
sinc
ncc
plate
contain
high
densiti
known
bioactiv
normal
percent
inhibit
method
appli
data
analysi
normal
rel
inhibit
valu
calcul
compound
subtract
valu
averag
plate
vehicl
control
follow
divid
result
differ
mean
plate
vehicl
posit
control
hit
candid
defin
compound
show
inhibit
normal
signal
intens
either
viral
target
analysi
replic
plate
packag
employ
calcul
percent
inhibit
describ
follow
scale
plate
divid
normal
valu
well
median
absolut
deviat
plate
result
given
z
score
posit
z
score
reflect
potent
inhibit
dynam
rang
calcul
plate
ratio
geometr
mean
posit
neg
control
scifind
databas
packag
american
chemic
societi
use
queri
chemic
databas
hit
candid
structur
evalu
known
bioactiv
excel
prism
graphpad
softwar
packag
use
data
analysi
statist
signific
differ
two
sampl
group
assess
unpair
twotail
test
two
sampl
group
excel
twoway
analysi
varianc
anova
prism
combin
tukey
multipl
comparison
posttest
multipl
sampl
group
specifi
figur
legend
experiment
uncertainti
identifi
error
bar
repres
standard
deviat
sd
differ
version
replicationcompet
iav
strain
encod
luciferas
report
describ
recent
recombin
harbor
gaussia
open
read
frame
genom
segment
reportedli
replic
effici
genet
stabl
show
high
luciferas
activ
level
laboratori
iav
strain
requir
addit
exogen
trypsin
proteolyt
matur
ha
protein
prime
viral
entri
machineri
gain
independ
trypsin
activ
screen
plate
gener
analog
recombin
trypsinindepend
iavwsn
genet
background
figur
result
reciavwsn
gaussia
show
effici
replic
report
express
absenc
exogen
trypsin
figur
howev
signal
window
gaussia
remain
figur
toward
extend
assay
rang
substitut
gaussia
luciferas
recent
develop
nano
luciferas
nanoluc
figur
use
basic
substrat
chemistri
gaussia
renilla
luciferas
combin
small
protein
size
high
signal
intens
recov
reciavwsn
nanoluc
inde
return
sixfold
improv
signal
window
show
superior
absolut
luciferas
signal
intens
compar
reciavwsn
gaussia
figur
z
valu
either
case
far
exceed
suggest
assay
suitabl
autom
serial
passag
recombin
confirm
equival
genet
stabil
reciavwsn
gaussia
reciavwsn
nanoluc
comparison
luciferas
activ
rapidli
disappear
reciavwsn
nsgaussia
subject
passag
harbor
luciferas
open
read
frame
ns
genom
segment
figur
design
recombin
follow
strategi
outlin
recent
report
origin
evalu
dualmyxoviru
ht
protocol
found
iav
mevbas
report
express
overlap
wherea
origin
report
strain
show
substanti
delay
luciferas
express
rang
differ
inoculum
multipl
infect
moi
compar
rsv
mev
cell
cultur
notabl
diverg
celltocel
fusion
syncytia
format
infect
repres
hallmark
mev
cytopath
much
less
pronounc
case
rsv
therefor
hypothes
lower
rate
later
rsv
spread
may
caus
slower
report
express
kinet
ask
whether
hyperfusogen
rsv
variant
would
allevi
problem
previous
gener
rsv
recombin
e
substitut
fusion
f
protein
residu
render
hyperfusogen
test
effect
hyperfusogen
report
express
kinet
gener
firefli
strain
figur
analog
previous
describ
sinc
firefli
nano
luciferas
activ
base
distinct
substrat
chemistri
independ
quantifi
independ
natur
luciferas
report
includ
time
peak
report
activ
f
mutant
strain
less
half
strain
harbor
standard
f
figur
result
suggest
hyperfusogen
firefli
strain
suitabl
coinfect
screen
reciav
wsnnanoluc
attempt
purifi
firefli
prepar
contamin
firefli
protein
synthes
stock
growth
howev
note
gradient
ultracentrifug
layer
bead
chromatographi
purif
strategi
success
reduc
renilla
luciferas
contamin
comparison
remain
ineffici
firefli
luciferas
figur
consequ
signal
window
assay
base
firefli
strain
approxim
lower
achiev
renilla
figur
exclud
use
highdens
ht
applic
search
innov
approach
suppress
buildup
contamin
firefli
protein
growth
viru
stock
explor
use
small
moleculeassist
shutoff
smash
technolog
induc
protein
degrad
recent
develop
unlik
system
design
induc
protein
turnov
smash
function
singlechain
system
stabil
state
return
nearn
protein
ad
genet
tag
smash
consist
hepat
c
virusderiv
proteas
flank
strong
degron
domain
induc
proteasom
degrad
proteas
site
posit
intersect
smash
tag
target
protein
figur
normal
condit
autoproteolysi
separ
tag
return
nearn
target
protein
presenc
strong
inhibitor
clinic
candid
asv
howev
autoproteolysi
block
degron
domain
induc
rapid
degrad
tag
affix
target
protein
ad
smash
tag
firefli
open
read
frame
success
recov
correspond
firesmash
recombin
immunoblot
antibodi
direct
firefli
luciferas
confirm
effici
degrad
tag
protein
incub
presenc
asv
steadi
state
level
close
match
untag
firefli
luciferas
absenc
drug
figur
expect
asv
effect
progeni
viru
titer
figur
smash
tag
remain
stabl
multipl
passag
viru
strain
figur
howev
growth
firesmash
presenc
asv
reduc
firefli
luciferas
activ
approxim
figur
pave
path
improv
assay
perform
figur
increas
signal
window
firesmash
compar
firefli
figur
result
suggest
reciav
wsnnanoluc
firesmash
may
repres
suitabl
pair
dualpathogen
drug
discoveri
campaign
establish
suitabl
assay
condit
first
independ
infect
three
human
respiratori
cell
line
firesmash
reciav
wsnnanoluc
differ
multipl
infect
measur
rel
luciferas
activ
hour
postinfect
test
host
cell
prefer
report
strain
moi
rsvbase
report
express
reduc
cell
compar
two
cell
line
figur
compar
reduct
observ
iavbas
nanoluc
express
cell
figur
toward
valid
assay
screen
campaign
initi
appli
protocol
plate
format
panel
known
bioactiv
discret
antimyxoviru
activ
cytotox
compound
comparison
figur
rel
inhibit
calcul
normal
raw
data
control
well
receiv
vehicl
dmso
case
known
myxoviru
inhibitor
differ
antivir
profil
correctli
identifi
z
valu
figur
exceed
defin
robust
assay
previous
character
rsv
fusion
blocker
emerg
hit
confirm
hypothesi
use
panresist
rsvf
mutant
reliabl
suppress
discoveri
addit
undesir
rsv
entri
inhibitor
also
sensit
panresist
escap
mechan
recent
describ
base
proofofconcept
data
miniatur
assay
plate
format
screen
pilot
set
nation
compound
collect
ncc
quadrupl
quantifi
assay
suitabl
autom
hit
discoveri
determin
platetopl
daytoday
reproduc
addit
ad
previous
identifi
broadspectrum
myxoviru
inhibitor
ncc
set
refer
execut
ht
condit
valid
campaign
return
robust
z
valu
exceed
signal
window
greater
rsv
iav
respect
figur
ncc
test
librari
hit
candid
identifi
inhibit
primari
report
activ
greater
either
target
virus
tabl
major
hit
candid
previous
associ
divers
antivir
andor
cytotox
activ
graphic
represent
assay
valid
replic
zscore
profil
reveal
dual
myxoviru
protocol
show
high
platetopl
reproduc
figur
plot
individu
zscore
replic
function
mean
inhibit
valu
compound
viral
target
furthermor
reveal
strong
correl
normal
score
effect
size
hit
candid
figur
proofofconcept
hit
identif
singlerepl
screen
condit
appli
valid
assay
librari
pharmacolog
activ
compound
figur
campaign
yield
primari
hit
candid
hit
rate
posit
includ
amongst
other
known
antiinfluenza
viru
antirsv
inhibitor
zanamivir
ribavirin
protein
biosynthesi
blocker
ie
emetin
dnarna
synthesi
inhibitor
ie
pmeg
idarubicin
tabl
note
zanamivir
ribavirin
amantidin
antivir
drug
librari
licens
treatment
iav
andor
rsv
infect
sinc
reciavwsn
strain
use
screen
resist
channel
blocker
amantadin
assay
correctli
identifi
licens
therapeut
antimyxoviru
indic
compound
pick
tabl
supplement
inform
tabl
subject
cytotox
test
candid
reduc
cell
viabil
less
twice
screen
concentr
admit
autom
doserespons
test
compound
tabl
primari
screen
strain
interfer
luciferas
report
proteas
activ
smash
tag
address
parallel
test
standard
recrsv
report
strain
lack
f
resist
mutat
express
renilla
luciferas
share
substrat
chemistri
firefli
luciferas
compound
interfer
nanoluciferas
address
test
cell
transient
transfect
nanoluciferas
express
plasmid
confirm
pipelin
implement
counterscreen
exercis
sinc
licens
influenza
drug
zanamivir
select
inhibit
iav
report
whenev
possibl
activ
cytotox
concentr
select
hit
candid
calcul
assay
target
fourparamet
variabl
slope
regress
model
tabl
triptolid
ncc
testset
origin
demonstr
preferenti
activ
iav
report
strain
likewis
select
doserespons
test
sourc
result
candid
five
show
margin
inhibitori
effect
primari
screen
strain
inact
triptolid
return
si
cc
ec
valu
two
doserespons
test
remain
nine
viabl
primari
hit
either
block
preferenti
rsv
compound
iav
compound
report
express
suppress
report
strain
compound
figur
first
inspect
reveal
confirm
hit
classifi
three
distinct
group
licens
antivir
therapeut
zanamivir
ribavirin
ii
compound
document
broadspectrum
antivir
activ
nucleosid
analog
gemcitabin
inhibitor
purin
pyrimidin
biosynthesi
pathway
aminopterin
brequinar
respect
iii
compound
yet
extens
associ
antiorthoor
paramyxoviru
activ
fenretinid
pmeg
hydrat
tabl
fenretinid
select
inhibit
rsv
iav
report
strain
unaffect
highest
concentr
test
pmeg
hydrat
block
report
strain
although
potenc
rsv
approxim
higher
iav
result
demonstr
new
gener
recombin
rsv
iav
report
strain
gener
studi
combin
robust
screen
protocol
miniatur
format
assay
success
identifi
licens
therapeut
compound
known
antimyxoviru
activ
set
rsv
inhibitor
merit
mechanist
evalu
studi
develop
valid
dual
pathogen
myxoviru
ht
protocol
use
innov
protein
engin
technolog
simultan
discoveri
pathogenspecif
broad
spectrum
hit
candid
figur
sever
major
advantag
protocol
tradit
singl
pathogen
screen
first
gener
coinfect
screen
report
earlier
compar
consecut
screen
librari
individu
viral
target
dual
pathogen
protocol
use
replicationcompet
recombin
virus
show
superior
cost
resourc
effect
ii
screen
agent
use
new
approach
iav
rsv
clinic
signific
member
myxoviru
famili
iii
addit
identifi
broadspectrum
blocker
dual
readout
strategi
creat
bona
fide
intern
standard
well
exclud
cytotox
undesir
promiscu
compound
effect
pool
virusspecif
hit
candid
stage
primari
screen
iv
new
assay
system
restrict
host
cell
rang
applic
cell
line
permiss
iav
rsv
replic
includ
human
respiratori
epitheli
cell
v
current
assay
suitabl
multipl
cycl
infect
provid
flexibl
choic
inoculum
moi
allow
interrog
stage
viral
live
cycl
three
gener
ht
report
assay
develop
recent
year
identif
novel
influenza
viru
inhibitor
first
gener
assay
employ
influenza
virusactiv
report
second
gener
system
base
recombin
virion
one
viral
open
read
frame
substitut
report
gene
third
gener
influenza
viru
report
strain
harbor
report
addit
genet
inform
one
genom
segment
compar
tradit
cellbas
antiinfluenza
viru
ht
screen
major
case
simpli
monitor
virusinduc
cytotox
common
advantag
report
assay
quantit
readout
possibl
assay
miniatur
beyond
plate
scale
higher
accuraci
hit
identif
howev
first
gener
assay
requir
laborand
resourceintens
prepar
target
cell
popul
support
singl
cycl
infect
first
second
gener
assay
restrict
narrow
rang
suitabl
target
cell
line
contrast
third
gener
influenza
viru
report
assay
combin
high
signal
intens
broad
target
cell
flexibl
therefor
explor
strategi
found
recent
develop
nano
luciferas
technolog
particularli
suitabl
influenza
report
viru
ht
applic
due
small
size
superior
signal
intens
translat
robust
assay
paramet
natur
primari
screen
hit
block
reciav
wsnnanoluc
report
strain
must
counterscreen
panel
current
circul
iav
strain
differ
genotyp
assess
full
antiiav
indic
spectrum
studi
spotlight
introduct
hyperfusogen
f
mutat
rsv
report
strain
acceler
luciferas
express
kinet
level
previous
observ
mev
report
strain
although
mev
rsv
repres
distinct
paramyxoviru
subfamili
littl
reason
assum
differ
report
express
kinet
rsv
mev
strain
due
substanti
faster
entri
mev
slower
gene
express
rsv
compar
mev
result
rather
indic
enhanc
celltocel
fusion
activ
mutant
rsv
report
strain
thu
acceler
later
spread
cell
monolay
alter
report
express
profil
previous
report
f
mutat
caus
rsv
panresist
known
character
smallmolecul
rsv
entri
inhibitor
includ
current
consid
clinic
use
advantag
engin
f
substitut
screen
strain
therefor
twofold
firstli
hyperfusogen
contribut
synchron
iav
rsv
report
express
profil
secondli
mutat
effici
suppress
discoveri
addit
rsv
entri
inhibitor
likewis
sensit
panresist
mechan
therefor
littl
clinic
potenti
consist
hypothesi
known
rsv
entri
inhibitor
spike
proofofconcept
screen
librari
emerg
hit
candid
assay
valid
screen
fluoresc
recombin
rsv
report
strain
gener
decad
ago
recent
pioneer
applic
luciferas
report
technolog
rsv
system
recoveri
recrsv
report
strain
sinc
gaussia
renilla
nano
luciferas
depend
substrat
chemistri
small
nano
luciferas
orf
suitabl
stabl
incorpor
recombin
influenza
viru
strain
coinfect
screen
demand
develop
rsv
firefli
report
strain
combin
reciav
wsnnanoluc
viru
recoveri
straightforward
high
level
contamin
firefli
luciferas
protein
viru
stock
despit
extens
purif
viru
prepar
prohibit
assay
miniatur
due
unaccept
low
sb
ratio
remark
problem
surfac
earlier
work
use
recrsv
report
two
explan
variat
purif
success
conceiv
firefli
renilla
luciferas
may
nonspecif
absorb
rsv
particl
firefli
luciferas
may
incorpor
effici
bud
rsv
virion
either
scenario
would
render
protein
inaccess
purif
strategi
design
preserv
infect
viru
stock
varieti
differ
approach
develop
control
protein
steadi
state
level
cellulo
howev
recent
pioneer
smash
technolog
oper
singlechain
system
return
stabil
protein
nearn
state
repeat
passag
rsv
recombin
harbor
firesmash
open
read
frame
furthermor
confirm
tag
genet
stabl
rsv
background
featur
make
technolog
uniqu
suitabl
applic
recombin
virion
allow
instanc
control
shutoff
viru
replic
vitro
vivo
appli
report
virus
ht
smash
provid
effect
strategi
remov
purificationresist
report
protein
viru
stock
test
screen
librari
format
use
fulli
valid
assay
correctli
identifi
licens
antivir
therapeut
present
librari
addit
gemcitabin
reportedli
antiretrovir
antiinfluenza
viru
activ
compound
block
purin
pyrimidin
biosynthesi
recogn
sever
previou
drug
screen
broadspectrum
antivir
taken
togeth
hit
group
ii
emerg
assay
therefor
fulli
consist
known
antivir
profil
gener
confid
accuraci
hit
discoveri
protocol
confirm
hit
fenretinid
select
block
rsv
assay
fenretinid
synthet
retinoid
deriv
develop
anticanc
anticyst
fibrosi
endpoint
compound
also
suppress
hiv
infect
origin
attribut
enhanc
viral
endocytosi
howev
recent
studi
demonstr
strong
antidengu
viru
activ
suggest
upregul
host
cell
unfold
protein
respons
pathway
altern
mechan
activ
select
opioid
delta
receptor
antagonist
highli
differenti
activ
rsv
iav
doserespons
counterscreen
exclud
high
cytotox
underli
caus
rsv
inhibit
compar
potenc
rsv
rsv
firesmash
distinct
report
technolog
argu
report
interfer
opioid
receptor
present
epitheli
cell
oralrespiratori
tract
remark
alter
opioid
receptor
signal
found
correl
diseas
sever
human
rsv
infect
mous
model
underscor
mechanist
evalu
role
opioid
receptor
signal
rsv
replic
may
uncov
novel
druggabl
target
assess
broader
paramyxoviru
indic
spectrum
fenretinid
character
underli
mechan
select
rsv
inhibit
current
underway
pmeg
hydrat
block
iav
rsv
report
strain
compound
acycl
nucleotid
analog
result
dna
chain
termin
convers
activ
diphosph
pmegpp
incorpor
prodrug
pmeg
develop
topic
treatment
human
papillomaviru
infect
second
prodrug
analog
act
antineoplast
dog
nonhodgkin
lymphoma
unaccept
safeti
profil
halt
human
trial
wherea
dual
pathogen
approach
inher
reduc
frequenc
undesir
compound
pool
virusspecif
hit
broadspectrum
candid
must
expect
includ
substanti
portion
cytotox
promiscu
entri
test
screen
half
hit
candid
block
report
strain
reveal
cytotox
exceed
cutoff
valu
followup
counterscreen
highlight
wide
antivir
indic
spectrum
often
penal
link
acut
chronic
cytotox
report
virusspecif
hit
compound
may
act
report
interfer
case
recrsv
firesmash
inhibit
hcvderiv
proteas
tradit
viru
yieldbas
secondari
screen
suitabl
address
assay
interfer
proteas
blockag
labor
resourc
intens
gener
divers
panel
myxoviru
report
strain
harbor
distinct
luciferas
demonstr
feasibl
rapid
autom
counterscreen
strategi
examin
hit
candid
activ
luciferas
report
distinct
substrat
chemistri
case
recrsv
firesmash
approach
also
address
proteas
liabil
sinc
firesmash
replac
recrsv
renilla
predict
newli
develop
technolog
screen
strategi
report
applic
rang
clinicallyrelev
viral
target
prove
effect
rapidli
focus
development
effort
viabl
hit
candid
refer
web
version
pubm
central
supplementari
materi
develop
secondgener
recrsv
report
strain
schemat
firefli
renilla
luciferas
genom
b
report
express
profil
infect
newli
gener
firefli
renilla
moi
instrument
gain
valu
repres
cellassoci
luciferas
activ
normal
highest
signal
seri
n
mean
sd
shown
purif
firefli
recrsvl
renilla
progeni
virion
differ
techniqu
rlu
viru
stock
purif
determin
background
clearanc
rlu
rlu
calcul
n
mean
sd
shown
ttest
p
signal
window
recrsv
report
strain
cell
expos
infect
inhibitor
rsv
rdrp
activ
vehicl
dmso
volum
equival
rlu
determin
hour
postinfect
valu
normal
vehicl
control
n
mean
sd
shown
number
column
show
raw
data
mean
sd
firesmash
allow
induc
report
degrad
schemat
firesmash
cassett
insert
genom
cleav
hcv
cleavag
site
b
immunodetect
firefli
luciferas
infect
cell
specifi
strain
presenc
absenc
inhibitor
asunaprevir
asv
sdspage
cell
lysat
cellular
gapdh
level
determin
load
control
c
peak
firesmash
progeni
titer
incub
presenc
asv
vehicl
dmso
n
mean
sd
shown
immunodetect
firefli
luciferas
serial
passag
firesmash
reinfect
cell
presenc
absenc
asv
passag
passag
shown
gapdh
level
determin
load
control
e
firefli
activ
growth
firesmash
presenc
absenc
asv
cell
infect
specifi
moi
harvest
hour
postinfect
n
mean
sd
shown
ttest
p
p
f
signal
window
firesmash
report
strain
calcul
describ
figur
n
mean
sd
shown
number
column
show
raw
data
mean
sd
z
sb
valu
specifi
graph
g
foldchang
contamin
firefli
luciferas
gradient
purif
firefli
firesmash
prepar
unpurifi
firefli
n
mean
sd
shown
ttest
p
assay
miniatur
valid
coinfect
cell
firesmash
reciav
wsnnanoluc
specifi
figur
plate
format
known
rsvspecif
iavspecif
mevspecif
inhibitor
broadspectrum
antivir
ribavirin
cytotox
cycloheximid
use
assay
valid
n
mean
sd
shown
b
coinfect
assay
paramet
obtain
manual
one
plate
n
mean
sd
shown
autom
four
plate
n
mean
sd
shown
format
broadspectrum
myxoviru
inhibitor
use
refer
compound
avr
dynam
rang
mean
dynam
rang
across
replic
plate
nd
determin
c
zscore
profil
autom
dualpathogen
pilot
screen
ncc
collect
plate
format
four
replic
symbol
mark
zscore
individu
replic
screen
solid
black
line
repres
assay
zscore
mean
dash
black
line
show
hit
cutoff
assay
mean
assay
zscore
sd
final
screen
concentr
individu
zscore
replic
repl
iiv
screen
shown
c
plot
function
mean
inhibit
compound
dash
horizont
vertic
black
line
show
hit
cutoff
base
zscore
assay
mean
assay
zscore
sd
biolog
effect
mean
inhibit
respect
number
repres
pearson
correl
coeffici
r
confid
interv
test
screen
lopac
librari
known
bioactiv
overal
z
zscore
profil
autom
proofofconcept
screen
lopac
librari
format
solid
green
line
show
zscore
mean
dash
black
line
hit
cutoff
assay
mean
assay
zscore
sd
recrsv
firesmash
assay
mean
assay
zscore
sd
rec
iav
wsnnanoluc
final
screen
concentr
b
doserespons
assay
hit
candid
concentr
conc
rang
hit
cc
concentr
confirm
inhibit
least
one
primari
target
viru
shown
valu
normal
norm
vehicl
dmso
treat
infect
repres
mean
inhibit
cell
viabil
viab
three
replic
sd
regress
curv
antivir
black
cytotox
grey
activ
base
fourparamet
model
applic
overview
replicationcompet
iav
rsv
report
strainbas
nextgener
dual
pathogen
ht
protocol
simultan
identif
iavspecif
rsvspecif
broad
spectrum
inhibitor
assay
valid
human
respiratori
cell
adapt
cell
line
permiss
either
viru
strain
infect
high
moi
predominantli
identifi
inhibitor
viral
entri
polymeras
low
moi
multicycl
infect
allow
interrog
stage
viral
live
cycl
counterscreen
requir
distinguish
hit
candid
report
interf
compound
specif
antivir
activ
hit
candid
report
interf
compound
cytotox
compound
promiscu
panassay
interf
pain
compound
broad
spectrum
activ
yan
